Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months. Akeso ...

Gilead Sciences has reported positive topline data from the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy and MSD’s ...

A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...

The DEPEND study demonstrates that checkpoint inhibitor nivolumab (Opdivo®) works best with high levels of PD-L1 biomarker, but does not work well with low levels of PD-L1 Multikine* is uniquely ...

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

including two complete responses in the 41-patient arm of EDGE-Gastric, and a six-month PFS of 77% overall. The greatest benefit was seen in patients whose tumours expressed high levels of PD-L1 ...

The first patient has been treated in a phase 1/2 clinical trial of an experimental Moderna vaccine designed to generate antibodies against PD-L1 and IDO1 – two targets thought to protect ...

Topic: Preclinical Data of IAR037, A Novel CD40/PD-L1 Bispecific Antibody for the Treatment of Advanced Solid Tumors Resistant to Immune Checkpoint Inhibitors ...